Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis

被引：0

作者：

Hauser, S. L. ^{[1
]}

Kappos, L. ^{[2
]}

Montalban, X. ^{[3
]}

Guittari, C. J. ^{[4
]}

Koendgen, H. ^{[5
]}

Li, C. ^{[5
]}

Marcillat, C. ^{[5
]}

Wormser, D. ^{[5
]}

Wolinsky, J. S. ^{[6
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Univ Basel, Univ Hosp Basel, Basel, Switzerland

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Genentech Inc, San Francisco, CA 94080 USA

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] UTHealth, McGovern Med Sch, Houston, TX USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P676

引用

页码：324 / 325

页数：2

共 50 条

[11] Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser, Stephen L.
Kappos, Ludwig
Montalban, Xavier
Hughes, Richard
McNamara, John
Pradhan, Ashish
Wormser, David
Koendgen, Harold
Wolinsky, Jerry S.
NEUROLOGY, 2019, 92 (15)
[12] Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
Hauser, S. L.
Kappos, L.
Montalban, X.
Hughes, R.
Koendgen, H.
McNamara, J.
Pradhan, A.
Wormser, D.
Wolinsky, J. S.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 697 - 698
[13] Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
Hauser, S. L.
Kappos, L.
Montalban, X.
Chognot, C.
Jessop, N.
Pradhan, A.
Prajapati, K.
Wolinsky, J. S.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 607 - 608
[14] Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Kappos, Ludwig
Hauser, Stephen
Montalban, Xavier
Buffels, Regine
Chin, Peter
Li, Carrie
Mortensen, Deborah
Napieralski, Julie
Van Beek, Johan
Wormser, David
Wolinsky, Jerry
NEUROLOGY, 2017, 88
[15] Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis
Hauser, S.
Kappos, L.
Montalban, X.
Craveiro, L.
Hughes, R.
McNamara, J.
Pradhan, A.
Wormser, D.
Koendgen, H.
Wolinsky, J. S.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[16] Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Hauser, S. L.
Kappos, L.
Montalban, X.
Koendgen, H.
Li, C.
Marcillat, C.
Pradhan, A.
Wormser, D.
Wolinsky, J. S.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 334 - 334
[17] Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser, S. L.
Kappos, L.
Montalban, X.
Prajapati, K.
Koendgen, H.
Craveiro, L.
Hughes, R.
Pradhan, A.
Wolinsky, J.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 68 - 69
[18] Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser, Stephen L.
Kappos, Ludwig
Montalban, Xavier
Craveiro, Licinio
Chognot, Cathy
Hughes, Richard
Koendgen, Harold
Pasquarelli, Noemi
Pradhan, Ashish
Prajapati, Kalpesh
Wolinsky, Jerry S.
NEUROLOGY, 2021, 97 (16) : E1546 - E1559
[19] Safety of ocrelizumab in multiple sclerosis: Up to 11 years of updated analysis in patients with relapsing and progressive multiple sclerosis
Hauser, Stephen
Kappos, Ludwig
Montalban, Xavier
Chognot, Cathy
Pasquarelli, Noemi
Singh, Varinder
Incera, Elodie
Wolinsky, Jerry
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 333 - 334
[20] Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis
Mildiner, Sorcha
Malnick, Stephen
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1692 - 1693

← 1 2 3 4 5 →